Management Team

Dror Ben-Asher , CEO

Dror Ben-Asher, Co-Founder of RedHill, was previously with ProSeed Capital, a European corporate finance boutique. Mr. Ben-Asher is a graduate of the University of Oxford (M.Jur.) and completed LL.M. studies at Harvard University. At Harvard, Mr. Ben-Asher was also a Fulbright Scholar focusing on the pharmaceutical industry and markets, an Olin Fellow for Law, Economics and Business, and an Economics Teaching Fellow at Harvard’s Economics Department. Dror Ben-Asher received an LL.B. with distinction (First Class Honours) from the University of Leicester.

Reza Fathi PhD , Senior VP R&D

Prior to joining RedHill, Dr. Fathi served as Director of Research Operations at XTL Biopharmaceuticals. He was previously at VivoQuest, PharmaGenics, Metrigen, Enzo Biochem and the Harvard Institute of Chemistry and Cell Biology. Reza graduated from Rutgers University (Ph.D. and Post-Doctoral Fellow) and Texas Tech University (BSc).

Gilead Raday , Chief Operating Officer

Gilead Raday previously served as interim CEO of Sepal Pharma, and as a director at TK Signal and Morria Biopharmaceuticals. He is a graduate of the University of Cambridge (M.Sc in Bioscience Enterprise) and the Hebrew University of Jerusalem (M.Sc Neurobiology, BSc Mathematics and Biology).

Adi Frish , Senior VP Business Development and Licensing

Adi Frish brings extensive business development and transactional experience to RedHill. Prior to joining RedHill, he served as VP Business Development at Medigus (TASE: MDGS). Mr. Frish was previously a partner at Y. Ben-Dror & Co. He is a graduated of Bar Ilan University (LL.M.) and Essex University (LL.B. with Honors).

Micha Ben Chorin , CFO

Mr. Ben Chorin has over 20 years of financial management experience with specific expertise in financing, M&A and international operations. He was a member of the team that built GVT (currently Telefonica Brazil). Most recently, Mr. Ben Chorin served as CFO of Pyramid Analytics and he previously served as CFO of Starhome B.V. Mr. Ben Chorin holds an M.A. and a B.A. from Tel-Aviv University and is a Certified Public Accountant. 

Guy Goldberg , Chief Business Officer

Prior to joining RedHill, Guy Goldberg served as Senior Vice President of Business Operations at Eagle Pharmaceuticals, a specialty injectable drug development company, based in New Jersey. Previously, Mr. Goldberg was a member of the investment team at ProQuest Investments, a healthcare focused venture capital firm. He previously served as a consultant at McKinsey & Company and holds a B.A. in Economics and Philosophy from Yale University and a J.D. from Harvard Law School.

Ira Kalfus MD , Medical Director

Prior to joining RedHill, Dr. Kalfus served as VP of Medical Affairs at Lev Pharmaceuticals. He was previously with Aetna/US Healthcare, Hillside Medical Associates (Internist), and Long Island Jewish Medical Center (President of the Staff Society and Chairman of Performance Improvement). Dr. Kalfus completed his residency in Internal Medicine at LIJ and is a graduate of the Albert Einstein College of Medicine (M.D.) and Columbia University (B.A. in Biology).

Terry F. Plasse MD , Medical Director

Dr. Plasse has extensive experience in drug development, primarily in oncology, having worked with several large as well as small pharmaceutical and biotech firms. He was previously Director for Oncology for North America at Rhone-Poulenc Rorer and served as a consultant to several major firms, including Chiron, Merck and Bristol-Myers Squibb. Dr. Plasse completed his fellowship in medical oncology at Mt Sinai Medical Center and his medical residency at Beth Israel Hospital, both in New York. He is a graduate of the Washington University School of Medicine, St. Louis, and received his BA from Brandeis University, in Waltham, MA.

Mark L. Levitt, MD, PhD, Medical Director, Oncology

Dr. Levitt is a Board Certified Medical Oncologist and Internist in the US and is Specialty Certified as an Oncologist (Medical and Radiation) and Internist in Israel. Prior to joining RedHill, Dr. Levitt served as Head of the Oncology Therapeutic Area, Global Business Development. Dr. Levitt also previously served as Head of the Lung Cancer Unit at Sheba Medical Center and held positions at Inotek Pharmaceuticals and in leading US universities. Dr. Levitt completed his internship and residency in Internal Medicine at Hahnemann University Hospital and his fellowship in Medical Oncology at the National Cancer Institute (NIH).

Shani Maurice , VP Business Development & Communications

Shani Maurice previously served as a Project Manager and as a Research Analyst at the Prime Minister’s Office, leading technological projects. She is a graduate of the Hebrew University of Jerusalem (B.Sc. in Biology and Business Administration).

Patricia Anderson , VP, Regulatory Affairs

Patricia Anderson has over 30 years of experience in regulatory affairs, developing numerous successful submissions to regulatory agencies across North America and Europe. Prior to joining RedHill, Ms. Anderson served as VP of Regulatory Services at MAPI SRS and as a member of the Executive Steering Committee for SRS, responsible for the business unit for regulatory consulting. She also served in various regulatory affairs positions at PharmApprove International Regulatory Consultants, Hyal Pharmaceutical Corporation and Bayer Canada. Ms. Anderson graduated with a B.Sc. in Biology from York University and received a Regulatory Affairs Certification (RAC) from the Regulatory Affairs Professional Society. Ms. Anderson was also honored as a Fellow of the Regulatory Affairs Professional Society.

Aida Bibliowicz , VP, Clinical Affairs Europe

Aida Bibliowicz has wide-ranging experience in drug development and clinical development international programs. Prior to joining RedHill Ms. Bibliowicz worked as Director, Project Management and Regulatory Affairs at Cato Research Israel, overseeing large multinational clinical studies in various indications. Ms. Bibliowicz holds a M.Sc. in Quality Assurance and Reliability from the Israel Institute of Technology, Technion, and an MBA from the Tel Aviv University.

Danielle Abramson , PhD, Director, Intellectual Property & Research

Danielle Abramson has extensive experience developing, analyzing, and managing intellectual property portfolios for Life Sciences and Medical Device companies. Ms. Abramson received her Bachelor of Science in Mechanical Engineering from Binghamton University and her Doctor of Philosophy in Medical Sciences from Brown University. Danielle Abramson is registered to practice as a patent agent before the U.S. Patent and Trademark Office. Prior to joining RedHill, Ms. Abramson practiced patent law at the international law firm of Greenberg Traurig.

Clara Fehrmann , Director of Clinical Operations

Clara Fehrmann has extensive R&D experience in the pharmaceutical industry acquired across large pharma, biotech as well as contract research companies. Prior to joining RedHill, she served as Clinical Project Manager at Merck Canada, Inc. and in various drug development positions at Santhera Pharmaceuticals. Ms. Fehrmann has also served as Clinical Research Associate at ICON Clinical Research (Canada), Inc. She graduated with a B.Sc. in Microbiology and Immunology from McGill University in Montreal and holds an M.Sc. degree in Pharmaceutical Sciences from the University of Montreal, Canada.

Patrick Mclean , Product Manager

Prior to joining RedHill, Patrick Mclean accumulated extensive experience in various senior executive positions in pharmaceutical companies including Giaconda Limited (CEO and Acting Chairman), Axcan Pharma (Senior VP European Commercial Operations, VP Sales & Marketing, Canada & US), Cossette Health Group (General Manager) and Allard Pharma Communications (President). Mr. Mclean graduated from the University of Minnesota (B.S. Chemistry).

Patricia Bandeira , Product Manager, Oncology

Patricia Bandeira has bench to market experience in the pharmaceutical sector acquired through work in biotech, contract research and large pharma. Patricia served in Operations Management and Project Management at both Merck Canada, Inc. and Schering Plough Canada, Inc. She is a graduate of McGill University (B.Sc. in Biochemistry, minor in Biotechnology) and the John Molson School of Business of Concordia University (MBA).

Uri Hananel Aharon , Chief Accounting Officer

Uri Hananel Aharon previously served as a team manager at Ernst & Young as well as an accountant at BDO and has an extensive experience in auditing and financial consulting for companies traded on NASDAQ and the Tel Aviv Stock Exchange, both in the biotech and high-tech sectors. Mr. Hananel Aharon is a graduate of the Hebrew University (BA, Economics and Accounting) and the Academic College for Management (MBA, Business Taxation).